What Happens to Tysabri PML Risk After Treatment Ends?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational and Patient Safety

If you've stopped taking Tysabri, you may still wonder about the risk of progressive multifocal leukoencephalopathy (PML). The legacy of medical research has long emphasized that adverse effects can persist after treatment ends. This page covers what is known about PML risk after discontinuation, including monitoring recommendations and symptom recognition.

Medical Background and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations for filing a claim—is essential. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri increases the risk of PML, and three key factors are known to elevate this risk: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patient enrollment and understanding of the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways Linking Tysabri to PML

Tysabri works by binding to alpha-4 integrins on the surface of immune cells, preventing their migration into the central nervous system. This immunosuppressive effect reduces inflammation in conditions like multiple sclerosis but also impairs immune surveillance against the JC virus. In patients who are seropositive for anti-JCV antibodies, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic brain lesions of PML. The duration of therapy is a critical factor, as the risk increases with cumulative exposure, particularly after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

PML presents with a range of neurological symptoms that can include progressive weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis typically involves brain MRI showing multifocal white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. Early recognition is crucial because prompt discontinuation of Tysabri may improve outcomes, though many patients still experience severe disability or death (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Settlement Considerations

The prescribing information for Tysabri includes a boxed warning that clearly states the increased risk of PML and identifies the three major risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise regarding whether patients and healthcare providers were adequately informed about the magnitude of this risk, especially in the context of individual risk stratification. For affected patients in Ohio, settlement-related considerations involve evaluating the timeline between Tysabri exposure and documented harm. The statute of limitations for personal injury claims in Ohio is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this discovery date may be the time of diagnosis or when symptoms first appeared. Given that PML can develop months to years after starting Tysabri, patients should promptly seek legal counsel to assess their specific circumstances.

Timeline Between Exposure and Documented Harm

The duration of Tysabri treatment prior to PML onset can range from a few months to several years, with risk increasing after two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variable latency period complicates the determination of when the statute of limitations begins. Ohio courts typically apply the 'discovery rule,' meaning the clock starts when the plaintiff knew or should have known of the injury and its cause. For PML patients, this often aligns with the date of definitive diagnosis. Given the severity of PML, early legal consultation is advisable to preserve the right to pursue a settlement or lawsuit.

Conclusion

Tysabri-associated PML is a devastating condition with well-defined risk factors and a clear mechanistic basis. For Ohio patients, the statute of limitations for filing a claim is a critical consideration that depends on the timing of diagnosis and discovery of harm. The adequacy of warnings provided to patients and prescribers remains a central issue in settlement discussions. Affected individuals should seek both medical and legal guidance promptly to navigate the complexities of this situation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Ohio?

In Ohio, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this is often the date of diagnosis or when symptoms first appeared. It is crucial to consult an attorney promptly to preserve your rights.

What are the risk factors for developing PML while on Tysabri?

Three key factors increase the risk of PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the Tysabri prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.